Enovis (NYSE:ENOV) Director Acquires $24,847.82 in Stock

Enovis Corporation (NYSE:ENOV) Director Sharon Wienbar acquired 874 shares of the business’s stock in a transaction on Tuesday, November 10th. The shares were purchased at an average price of $28.43 per share, for a total transaction of $24,847.82. Following the purchase, the director directly owned 44,651 shares of the company’s stock, valued at $1,269,427.93. This represents a 2.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Enovis Stock Performance

NYSE:ENOV traded down $0.92 during trading hours on Thursday, reaching $27.63. 1,153,270 shares of the stock were exchanged, compared to its average volume of 1,886,113. The stock has a market capitalization of $1.59 billion, a P/E ratio of -3.00 and a beta of 1.31. The firm has a 50 day simple moving average of $20.36 and a 200-day simple moving average of $23.19. The company has a quick ratio of 1.08, a current ratio of 2.15 and a debt-to-equity ratio of 0.82. Enovis Corporation has a 52 week low of $16.70 and a 52 week high of $31.81.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.88 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.11. The business had revenue of $558.73 million during the quarter, compared to the consensus estimate of $557.12 million. Enovis had a positive return on equity of 13.23% and a negative net margin of 22.86%. The business’s quarterly revenue was up 1.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.75 EPS. As a group, sell-side analysts forecast that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on ENOV shares. Citizens Jmp decreased their price objective on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a report on Wednesday, September 2nd. Canaccord Genuity Group dropped their target price on shares of Enovis from $45.00 to $42.00 and set a “buy” rating on the stock in a report on Friday, November 6th. UBS Group restated a “buy” rating and issued a $44.00 price target on shares of Enovis in a research report on Monday, October 5th. Wall Street Zen raised shares of Enovis from a “hold” rating to a “buy” rating in a report on Saturday, October 31st. Finally, BMO Capital Markets set a $27.00 price objective on shares of Enovis in a research report on Tuesday, September 1st. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $38.62.

Institutional Trading of Enovis

Several hedge funds have recently made changes to their positions in ENOV. Bank of America Corp DE acquired a new position in Enovis during the 2nd quarter valued at approximately $11,502,000. First National Bank of Omaha bought a new position in Enovis during the 2nd quarter worth $1,250,000. Legal & General Group Plc acquired a new stake in Enovis in the second quarter worth $2,753,000. Man Group plc acquired a new stake in Enovis in the second quarter worth $8,711,000. Finally, Jupiter Topco LLC acquired a new stake in Enovis in the second quarter worth $2,346,000. Institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.